Flumatinib versus imatinib for newly diagnosed CML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study compares two targeted pills—flumatinib and imatinib—in people newly diagnosed with chronic-phase CML (a blood cancer). It aims to see which one works better and is safer soon after diagnosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have chronic-phase CML with the Philadelphia chromosome (Ph+ CML), diagnosed within the last 6 months
- Your overall health/activity level is ECOG 0 to 2 (able to care for yourself and do light activities)
- You can sign a consent form and agree to join the study
- You have NOT already had a specific cancer mutation called T315I
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (HS-10382 plus another drug) for people with chronic myeloid leukemia (CML) whose current treatments have stopped working or caused side effects. It may help if you have a certain type of CML that is not controlled by previous therapies.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
This trial studies whether a generic version of imatinib (Carcemia®) works as well and is as safe as Glivec® in real-life care for people newly diagnosed with chronic phase chronic myeloid leukemia (CML). It may help confirm that the generic option is effective for controlling the disease.
This study tests clifutinib (a targeted medicine) combined with chemotherapy in people newly diagnosed with AML. It aims to see if this combination is safer and more effective, including in older adults and people who may not tolerate strong chemotherapy.
This trial is testing a new pill for people with intermediate or high-risk myelofibrosis, a type of bone marrow cancer. It aims to see if the drug can help manage the disease and offer a new treatment option for those who may have limited choices.
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
Hear when a new CML, Chronic Phase trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.